Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: What's on the horizon

Journal of Cardiology

Volumn 48, Issue 5, 2006, Pages 235-241

  Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; NATRIURETIC FACTOR;

ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; FIBROBLAST; HEART MUSCLE CELL; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CARDIOVASCULAR DISEASES; COLLAGEN; DRUG DELIVERY SYSTEMS; FIBROBLASTS; HUMANS; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDES;

EID: 34248147132     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, Bielinski V, Barylko B, Redfield MM, Burnett JC Jr: Membrane guanylyl cyclase receptors: An update. TrendsEndocrinolMetab2006; 17: 251-258
2. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A: Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995; 378: 65-68
3. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N: Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad SciUSA1997;94: 14730-14735
4. Holtwick R, van Eickels M, Skryabin BV, B,aba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M: Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003; 111: 1399-1407
5. Patel JB, Valencik ML, Pritchett AM, Burnett JC Jr, McDonald JA, Redfield MM: Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005; 289: H777-H784
6. Tokudome T, Horio T, Kishimoto I, Soeki T, Mori K, Kawano Y, Kohno M, Garbers DL, Nakao K, Kangawa K: Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic pep-tides. Circulation 2005; 111: 3095-3104
7. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr: Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-1134
8. Calderone A, Bel-Hadj S, Drapeau J, El-Helou V, Gosselin H, Clement R, Villeneuve L: Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. J Cell Physiol 2006; 207: 165-173
9. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA: B-type natriuretic peptide exerts broad functional opposition ot transforming growth factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453-461
10. Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield M, Matsuda Y, Burnett C Jr: BNP-induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors. Cell Physiol 2006; 209: 943-949[Epub ahead of print].
11. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97: 4239-4244
12. Hawkridge AM, Heublein DM, Bergen HR HI, Cataliotti A, Burnett JC Jr, Muddiman DC: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl AcadSciUSA2005; 102: 17442-17447
13. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC Jr, Malatino LS: Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol2006; 291: H1529-H1535
14. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH: Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005; 112: 2403-2410
15. Chan JC, Knudson O, Wu F, Morser J, Dole \VP, Wu Q: Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A 2005; 102: 785-790
16. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P: Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006; 48: 499-505
17. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M: A new member of the natriuretic peptide family is present in the venom of the green mamba ( Dendroaspis angusticeps). JBiolChem 1992; 267: 13928-13932
18. Best PJ, Burnett JC, Wilson SH, Holmes DR Jr, Lerman A: Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55: 375-384
19. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC: Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999; 56: 502-508
20. Singh G, Kuc RE, Maguire JJ, Fidock M, Davenport AP: Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: Downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006 ;99: 183-190
21. Margulies KB, Burnett JC Jr: Visualizing the basis for paracrine natriuretic peptide signaling in human heart. Circ Res2006; 99: 113-115
22. Chen HH, Lainchbury JG, Burnett JC Jr: Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002; 40: 1186-1191
23. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr: Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001; 37: 1089-1094
24. Wang W, Ou Y, Shi Y: AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy, of congestive heart failure. PharmRes2004; 21: 2105-2111
25. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr: Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation 2005; 112: 836-840
26. Deschepper CF: The many possible benefits of natriuretic peptides after myocardial infarction. Hypertension 2005; 46: 271-272
27. Michaels AD, Klein A, Madden JA, Chatterjee K: Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003; 107: 2697-2701
28. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004; 109: 1680-1685
29. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Yamaniuro M, Harada M, Saito Y, Nakao K, Kurihara H, Yasue H, Ogawa H: Inhibitory effect of natriuretic peptides on aldosterone syn-thase gene expression in cultured neonatal rat cardiocytes. Circulation2003; 107: 807-810
30. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001; 37: 1221-1227
31. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, Fukunaga Y, Sone M, Yurugi-Kobayashi T, Miyashita K, Tsujimoto H, Kook H, Feil R, Garbers DL, Hofmann F, Nakao K: Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A 2003; 100: 3404-3409
32. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Hone H, Ohnishi M, Kinoshita M: Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826